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ABSTRACT
HIV-1 reverse transcriptase (RT) connection subdo-
main mutations at positions 348, 369 and 376 have
been associated with resistance to non-nucleoside
RT inhibitors (NNRTIs). N348I may interfere with
the initiation of (+)-strand DNA synthesis by reduc-
ing polypurine tract (PPT) removal in the presence
of nevirapine. The effect of NNRTIs on the RNase
H-mediated cleavage of PPT-containing template-
primers has been studied with wild-type HIV-1 RT and
mutants N348I, T369I, T369V, T376S and N348I/T369I.
In the presence of NNRTIs, all RTs were able to stim-
ulate PPT cleavage after primer elongation. The en-
hancing effects of nevirapine and efavirenz were re-
duced in RTs carrying mutation N348I, and specially
N348I/T369I. However, those mutations had no ef-
fect on rilpivirine-mediated cleavage. Prior to elonga-
tion, the PPT remains resilient to cleavage, although
efavirenz and rilpivirine facilitate RNase H-mediated
trimming of its 3′-end. The integrity of the 3′-end is
essential for the initiation of (+)-strand DNA synthe-
sis. In the presence of dNTPs, rilpivirine was the most
effective inhibitor of (+)-strand DNA synthesis block-
ing nucleotide incorporation and preventing usage of
available PPT primers. The N348I/T369I RT showed
reduced ability to generate short RNA products re-
vealing a cleavage window defect. Its lower RNase H
activity could be attributed to enhanced rigidity com-
pared to the wild-type enzyme.
INTRODUCTION
The human immunodeficiency virus type 1 (HIV-1) reverse
transcriptase (RT) is a major target of antiretroviral ther-
apy (1–3). The HIV-1 RT is a DNA polymerase that can use
either DNA or RNA strands as templates for DNA synthe-
sis. The RT also possesses an RNase H activity responsi-
ble for the degradation of RNA in RNA/DNA complexes.
RT DNA polymerase and RNase H activities are needed to
convert the viral genomic RNA into double-stranded DNA
that integrates into the genome of the host cell. During
reverse transcription, the first DNA strand (i.e. (–)-strand
DNA) is synthesized by extending the 3′-end of a specific
tRNA using the viral RNA as template. The RT RNase H
activity degrades the RNA template, with the exception of
two short polypurine tracts (PPTs), located at the center and
at the 3′ end of the viral RNA genome. These PPTs are used
as major initiation sites for (+)-strand DNA synthesis. The
tRNA and PPT primers are later removed by the RNase H
activity of the RT (for reviews see (4,5)).
Inhibitors of the DNA polymerization activity consti-
tute the backbone of current therapies against HIV in-
fection and AIDS. These drugs can be classified into
nucleoside/nucleotide RT inhibitors (NRTIs) and non-
nucleosideRT inhibitors (NNRTIs). There are fiveNNRTIs
approved for clinical use: nevirapine, delavirdine, efavirenz,
etravirine and rilpivirine, although delavirdine is rarely used
due to its inferior antiviral efficacy and inconvenient dosing
schedule (3,6). The HIV-1 RT is a heterodimer composed of
subunits of 66 and 51 kDa (p66 and p51, respectively). The
NNRTI binding site is a hydrophobic pocket in the palm
subdomain of p66, ∼10 A˚ away from the polymerase ac-
tive site. Leu100, Lys101, Lys103, Val106, Thr107, Val108, Val179,
Tyr181, Tyr188, Val189, Gly190, Phe227, Trp229, Leu234, Pro236
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and Tyr318 in p66 and Glu138 in p51 delineate the NNRTI
binding pocket ((7,8); reviewed in (9)). NNRTIs have a low
genetic barrier and single amino acid substitutions affect-
ing residues at their binding pocket confer high-level resis-
tance to nevirapine, delavirdine and efavirenz (e.g. K103N
orY181C) (reviewed in (3)). Kinetic studies have shown that
NNRTIs slow the rate of the chemical reaction of nucleotide
incorporation (10,11). Based on structural studies, it has
been proposed that NNRTIs block reverse transcription by
(i) changing the mobility of the RT thumb subdomain, (ii)
distorting the catalytic triad formed by the side chains of
Asp110, Asp185 and Asp186 in p66 or (iii) by repositioning
the primer grip in a non-active conformation (reviewed in
(2,9)).
Apart from their inhibitory effects on DNA polymeriza-
tion, it has been shown that nevirapine and efavirenz stim-
ulate the RNase H activity of HIV-1 RT ((12–14); reviewed
in (15)). The HIV-1 RT can bind nucleic acid substrates in
one of the two orientations. Single-molecule spectroscopy
studies using PPT-containing RNA/DNA hybrids mimick-
ing the initiation of (+)-strand DNA synthesis showed that
the 3′ end of the PPT could be located at the DNA poly-
merase catalytic site (polymerase-dependentmode) or at the
RNase H active site (16,17). Nevirapine and efavirenz pro-
mote binding in a polymerase-independent mode, thereby
facilitating the cleavage and subsequent removal of the PPT
(16,17). On the other hand, the presence of dNTPs favors
binding in a polymerase-dependent mode, thereby facilitat-
ing the addition of nucleotides at the 3′ end of the PPT and
the initiation of (+)-strand DNA synthesis. This process is
particularly sensitive to NNRTI inhibition (18), while pre-
mature removal of the PPT impairs reverse transcription
(19). Several studies have shown that NNRTIs, such as nevi-
rapine or efavirenz, canmodulateRNaseH activity through
long-range interactions that depend on the structure of the
RNA/DNAhybrid ((14,20–22); reviewed in (15)). However,
little is known about the effects of recently approved di-
arylpyrimidines such as etravirine or rilpivirine.
Several studies have demonstrated that mutations in the
connection subdomain and the RNase H domain of HIV-
1 RT can have an impact on resistance to RT inhibitors
((23–26); reviewed in (27)). Specifically, mutations away
from the NNRTI binding pocket such as N348I, T369I or
V and A376S confer low-to-moderate levels of resistance
to nevirapine and delavirdine in phenotypic assays carried
out with recombinant HIV-1 (28,29). Furthermore, HIV-1
clones carrying RT mutations N348I and T369I show high-
level resistance to both drugs and moderate resistance to
efavirenz, although the presence of both mutations confers
a severe fitness defect (28,29). The increased prevalence of
N348I and A376S in treated patients has been related to
previous exposure to nevirapine while the presence of those
mutations has been associated with an increased risk of vi-
rological failure (30,31). Both amino acid substitutions con-
fer increased affinity for the template-primer (31,32), while
N348I reduces the association rate of the RT and nevirap-
ine (32). However, Asn348 and Ala376 are away from the
NNRTI binding pocket and their effects on NNRTI resis-
tance can be explained only by assuming long-range in-
teractions along the nucleic acid binding cleft. N348I has
a detrimental effect on the RNase H activity of the RT
(30,33). During (+)-strand DNA synthesis, nevirapine and
efavirenz facilitate the premature removal of the PPT by fa-
voring its binding in a polymerase-independent orientation
(16), although it has been shown that the presence of N348I
could attenuate the effects of nevirapine (19).
In this work, we have extended these analyses to re-
cently approved inhibitors (etravirine and rilpivirine) as
well as other RT connection subdomain mutations that
have been associated with resistance to NNRTIs. Our study
provides mechanistic insight into how the double-mutant
N348I/T369I in HIV-1 RT could affect PPT removal and
RNase H cleavage specificity in the absence or presence of
NNRTIs.
MATERIALS AND METHODS
Mutagenesis, expression and purification of recombinant RTs
Wild-type (WT) HIV-1BH10 RT and mutant K103N were
obtained as previously described (31,34). Other mutants
were obtained after site-directed mutagenesis using the
standard QuikChangeTM protocol (Stratagene). Briefly,
complementary mutagenic primers (Supplementary Table
S1) were used to amplify the entire plasmid p66RTB that
contained the WT RT-coding sequence of the HIV-1BH10
strain, in a thermocycling reaction carried out with the
high-fidelity Pfu DNA polymerase. After mutagenesis, the
entire RT-coding regions were sequenced and, if correct,
used for RT expression and purification. Mutant and WT
RTs were obtained as heterodimers composed of subunits
of 66 and 51 kDa (p66 and p51, respectively), with a poly-
histidine tag at theC-terminus of p66 (34,35). Enzymeswere
quantified by active site titration before biochemical studies
(36).
Nucleotides, template-primers and NNRTIs
Stock solutions (100 mM) of deoxyribonucleoside triphos-
phates (dNTPs) were obtained from GE Healthcare. [ -
32P]ATP (10 mCi/ml; 3000 Ci/mmol) was provided by
Perkin Elmer. Synthetic oligonucleotides were obtained
from Life Technologies and Sigma. Template-primers used
in nucleotide incorporation and RNase H activity assays
are given in Supplementary Table S2. RT inhibitors were
obtained from the AIDS Research and Reference Reagent
Program,Division of AIDS, NIAID,NIH (where etravirine
and rilpivirine were supplied to the Program by Tibotec
Pharmaceuticals, Inc.).
Nucleotide incorporation and RT inhibition assays
Assays were carried out with template-primer D38/25PGA
(Supplementary Table S2). The primer was labeled at its 5′
end with 1 Ci of [ -32P]ATP and 5 U of T4 polynucleotide
kinase (Promega) in 70-mM Tris-HCl pH 7.6 buffer con-
taining 10-mMMgCl2, 5-mM dithiothreitol (DTT) and 10-
M adenosine triphosphate (ATP). Template and primer
were annealed in 150-mM NaCl and 150-mM magnesium
aspartate, the template/primer molar ratio was adjusted to
1:1 and the final concentration was 300 nM. Nucleotide
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incorporation assays in the absence or presence of NNR-
TIs were carried out in a total volume of 12 l. A prein-
cubation mix (5 l) of purified RT (14.4–36 nM) and la-
beled template-primer (72 nM)wasmaintained at 37oCdur-
ing 10 min in 120-mM Hepes pH 7.0 buffer, containing
24-mM NaCl, 24-mM MgCl2, 208-mM potassium acetate,
1.6-mM DTT and 8% (w/v) polyethyleneglycol 6000, and
then mixed with 3 l of 4% dimethyl sulfoxide (DMSO) or
appropriate concentrations of the corresponding NNRTI
(in 4% DMSO). Then, the sample was incubated for 10
min at 37oC. Four microliter of a solution containing 100-
M 2´-deoxythymidine 5´-triphosphate (dTTP), diluted in
130-mM potassium acetate, 1-mM DTT and 5% (w/v)
polyethyleneglycol 6000 was added and the reaction was
then stopped after 20 s by mixing an aliquot of 4 l with an
equal volume of stop solution (10-mM ethylenediaminete-
traacetic acid in 90% formamide containing 3-mg/ml xy-
lene cyanol (FF) and 3-mg/ml bromophenol blue) and heat-
ing at 90oC for 10 min. Samples were analyzed by dena-
turing polyacrylamide gel electrophoresis and quantified by
phosphorimaging. NNRTI inhibition was determined from
the relative amounts of dTTP incorporated in the pres-
ence of different NNRTI concentrations, compared with
nucleotide incorporation in the absence of drug. The IC50
values for each inhibitor were obtained from the inflection
points in the corresponding dose-response curves.
RNase H activity assays
Template-primers used in these assays are listed in Supple-
mentary Table S2 and include RNA/DNA complexes, as
well as a complex containing a DNA strand and a chimeric
RNA–DNA primer (e.g. T57d/PPT17r8d). Assays were
carried out in 50-mM Tris-HCl pH 8.0 buffer, containing
50-mMNaCl and 5-mMMgCl2 (37). Template-primer con-
centrations were usually in the range 25–50 nM, and RT
concentrations varied between 25 and 125 nM, depending
on the assays. A 2- to 5-fold excess of enzyme over template-
primer was used in all assays. Reactions were initiated by
addingMgCl2. Aliquots were removed at appropriate times
(usually between 20 s and 5 min) and quenched with an
equal volume of stop solution. In assays carried out under
single-turnover conditions, RTs and template-primers were
preincubated for 5 min at 37oC and reactions were then ini-
tiated by addingMgCl2 and sodiumheparin to final concen-
trations of 5 mM and 3 mg/ml, respectively. Products were
analyzed by denaturing polyacrylamide gel electrophoresis
and quantified by phosphorimaging. The amount of hy-
drolyzed product generated over time was fitted to a single-
exponential decay equation: [P]=A× e−kobs × t, where kobs
is an apparent kinetic constant of the RNase H cleavage re-
action.
HIV drug susceptibility assays
Recombinant HIV-1 variants were obtained after co-
transfecting MT-4 cells with an RT-deleted HXB2-D clone
previously linearized with BstEII and a polymerase chain
reaction product containing the nucleotide sequence encod-
ing for the 66-kDa subunit of the RT (38). The RT-coding
region of recovered viruses was fully sequenced in order to
check for reversions or undesiredmutations.MT-4 cells and
the deleted HXB2-D clone were obtained from the AIDS
Reagent Program (Medical Research Council). MT-4 cells
were used to propagate the recombinant virus. Their sus-
ceptibility to RT inhibitors was determined as previously
described, using a multiplicity of infection of 0.003 (37).
RESULTS
Previous reports have shown that mutations affecting
residues away from the NNRTI binding pocket confer low-
to-moderate resistance to nevirapine and delavirdine, and in
a lesser extent to efavirenz ((28,29); reviewed in (27)). Phe-
notypic assays carried out in MT-4 cells with recombinant
HIV-1 bearing mutations N348I, T369I, T369V, T376S and
the double mutant N348I/T369I were consistent with pre-
vious estimates and revealed that the double mutant shows
significant resistance to nevirapine (Table 1). On the other
hand, none of the tested mutations had a significant impact
on resistance to efavirenz, etravirine or rilpivirine. These re-
sults were broadly consistent with the IC50 values obtained
with recombinant RTs in nucleotide incorporation reac-
tions using heteropolymeric DNA/DNA template-primers,
although the N348I/T369I RT showed low-level resistance
to rilpivirine in these assays (Supplementary Table S3).
Effect of RT connection subdomain mutations on PPT re-
moval
The selection of N348I and other mutations under therapy
withNNRTIs, particularly with nevirapine, could be related
to effects in other steps of the reverse transcription process.
It has been previously shown that initiation of (+)-strand
DNA synthesis is particularly sensitive to NNRTI inhibi-
tion (18), while PPT removal is a critical step at the initia-
tion of (+)-strand DNA synthesis.
Template-primers mimicking the initial steps of (+)-
strand DNA synthesis were used to study the effects
of RT mutations on PPT removal. In one of them
(T57d/PPT17r8d) the shorter strand was a chimeric RNA–
DNA oligonucleotide that contained the PPT sequence
located at the 3′ end of the HIV-1 genome (17 ribonu-
cleotides), with an 8-nt extension ofDNA.As shown in Fig-
ure 1A,RT connection subdomainmutations T369I, T369V
and T376S had a minor effect on the RT’s ability to cleave
the PPT17r8d oligonucleotide at position –17 (G↓A site)
that corresponds to the RNA(PPT)–DNA junction. How-
ever, as in the case of mutant T369I shorter PPT products of
16 and 15 nucleotides were also observed in reactions car-
ried out with mutants T369V and T376S (data not shown).
N348I, particularly in combination with T369I, showed
very low efficiency in the RNase H cleavage reaction. Inter-
estingly, when the template-primer used was a complex con-
taining a 29-nt DNA and the 17-nt PPT RNA, we did not
observe any secondary cleavage and the PPT remained in-
tact (Figure 1B). This complex (PPT29DNA/PPT17r) was
used because it mimics the first step in (+)-strandDNA syn-
thesis. Its premature degradation by the RTRNase H activ-
ity would abort reverse transcription, since the integrity of
the 3′ end of the PPT is essential in this process (39,40).
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Table 1. Susceptibility of HIV-1 constructs to RT inhibitorsa
RT IC50 (nM)
AZT Nevirapine Efavirenz Etravirine Rilpivirine
WT 4.3 ± 0.6 15.0 ± 1.7 1.1 ± 0.2 1.0 ± 0.1 0.11 ± 0.01
K103N 14 ± 2 (3.2) 1831 ± 226 (>100) 44.5 ± 15.0 (42) 1.2 ± 0.4 (1.3) 0.13 ± 0.02 (1.2)
N348I 16.3 ± 1.5 (3.8) 33.0 ± 4.6 (2.2) 1.2 ± 0.3 (1.1) 1.2 ± 0.1 (1.2) 0.26 ± 0.10 (2.3)
N348I/T369I 5.0 ± 1.0 (1.1) 102.3 ± 2.5 (6.8) 1.4 ± 0.3 (1.3) 1.1 ± 0.1 (1.1) 0.08 ± 0.03 (0.7)
T369I 7.0 ± 1.0 (1.6) 28.3 ± 1.5 (1.9) 1.1 ± 0.1 (1.0) 1.0 ± 0.1 (1.0) 0.12 ± 0.03 (1.0)
T369V 18.7 ± 3.1 (4.3) 27.3 ± 11.8 (1.8) 1.0 ± 0.1 (1.0) 1.1 ± 0.1 (1.1) 0.27 ± 0.03 (2.5)
T376S 7.3 ± 1.5 (1.7) 26.0 ± 7.2 (1.7) 1.5 ± 0.2 (1.4) 1.4 ± 0.2 (1.4) 0.19 ± 0.05 (1.7)
aThe IC50 values shown are averages ± standard deviations of at least three tests, with each one performed six times. The fold increase in IC50 relative to
wild-type HXB2 virus control carrying the RT sequence of BH10 is shown between parentheses.
Figure 1. RNase H activity of WT and mutant HIV-1 RTs during (+)-strand DNA synthesis. (A) Representative gel showing the cleavage of the PPT17r8d
strand in the template-primer T57d/PPT17r8d complex (sequence given below) obtained with the WT RT and mutants N348I, T369I and N348I/T369I.
The T57d/PPT17r8d complex mimics a (+)-strand DNA synthesis intermediate where eight dNTPs have been added to the 17-nucleotide PPT-RNA
primer. The template-primer (25 nM) was incubated in the presence of RTs at 125-nM concentration. Aliquots were removed at 20 s, 40 s, and 1, 2, 3,
4 and 5 min. Arrows indicate the positions of the observed cleavages. Time courses of the RNase H cleavage reactions obtained with all tested RTs are
shown on the right (data were obtained from three independent experiments). (B) RNase H activity of WT, N348I/T369I and N348I mutant enzymes on
a PPT29DNA/PPT17r complex. This complex mimics the first intermediate in the (+)-strand DNA synthesis reaction, containing the RNA primer before
the incorporation of dNTPs.
Effects of NNRTIs on PPT removal by HIV-1 RTs bearing
mutations in the connection subdomain
Previous studies have shown an increase in PPT cleavage
efficiency in reactions carried out with the WT RT in the
presence of nevirapine and efavirenz (19). In addition, those
authors demonstrated that N348I alone counteracts the ef-
fect of nevirapine, and to a lesser degree, efavirenz. We have
now extended those observations to other RT connection
subdomain mutants as well as to the recently approved in-
hibitor rilpivirine. In all cases, NNRTI addition resulted in
a more efficient PPT cleavage of the chimeric RNA–DNA
substrate (Figure 2A). The largest effects were observed
at saturating concentrations (i.e. in the micromolar range),
and nevirapine and efavirenzwere stronger promoters of the
RNase H activity than rilpivirine. N348I alone or in com-
bination with T369I suppressed in part the enhancing ef-
fect of nevirapine and efavirenz on the RNase H activity
of the enzyme. In contrast, in reactions carried out in the
presence of rilpivirine, the endonucleolytic activity of mu-
tants N348I and N348I/T369I was similar to that observed
Nucleic Acids Research, 2015, Vol. 43, No. 4 2263
Figure 2. Effect of HIV-1 RT connection subdomainmutations on the RNase H cleavage of a PPT-containing template-primer in the presence of NNRTIs.
(A) Cleavage of the chimeric PPT(RNA)-DNA oligonucleotide in the T57d/PPT17r8d complex in the presence of increasing concentrations of nevirapine
(0, 0.08, 0.16, 0.32, 0.63, 1.25, 2.5 and 5 M). Template-primer and RT concentrations in these assays were 25 and 125 nM, respectively. Aliquots were
withdrawn after a 20-s incubation. C stands for control (uncleaved PPT17r8d primer). Graphical representations of the percentage of PPT17r8d primer
cleavage byWT and mutant RTs in the absence of drug or in the presence of 5-Mnevirapine, 12.5-M efavirenz or 5-M rilpivirine are shown below. (B)
Time courses of cleavage reactions carried out in the presence of nevirapine, efavirenz and rilpivirine. WT, N348I and/or N348I/T369I RTs (50 nM) were
mixed with 25-nM template-primer (T57d/PPT17r8d), and RNase H cleavage was monitored in the absence or presence of drug. Aliquots were removed
at 20 s, 40 s and 1, 2, 3 and 4 min. Cleavage products corresponding to bands of 17, 16 and 15 nucleotides are indicated in the gel. NVP, nevirapine; EFV,
efavirenz; RPV, rilpivirine.
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for the WT enzyme. The double mutant showed increased
cleavage efficiency in the presence of NNRTIs, but the dif-
ferences between rilpivirine and the other drugs were much
smaller. Interestingly, differences in PPT cleavage efficien-
cies between the WT and the double-mutant RT in the ab-
sence of inhibitor were largely reduced in the presence of
NNRTIs (Figure 2B). Thus, although the RNase H activity
of the N348I/T369I RT is very low, addition of NNRTIs
enhances its RNase H activity to similar levels as those ob-
served with the WT RT.
The increased efficiency of PPT removal mediated by NNR-
TIs is not observed in the presence of mutations that abolish
drug binding
The HIV-1 RT mutation K103N confers high-level resis-
tance to nevirapine and efavirenz due to the inability of
those drugs to bind the mutant RT. RNase H assays car-
ried out with this enzyme and the T57d/PPT17r8d com-
plex demonstrated that the inhibitor concentration had no
impact on the PPT cleavage efficiency of the RT (Supple-
mentary Figure S1A). However, NNRTI concentration in-
fluenced PPT removal in reactions carried out with both
WT and the double-mutant N348I/T369I, with highest ef-
ficiencies at 0.6–5-M nevirapine (Figure 2A and Supple-
mentary Figure S1A). In reactions carried out in the pres-
ence of dNTPs with the complex PPT29DNA/PPT17r that
mimics the initial step of (+)-strandDNA synthesis, themu-
tant K103N RT was able to extend the RNA primer with
similar efficiencies in the presence or absence of inhibitor
(Supplementary Figure S1B). On the other hand, the WT
RT was able to produce significant amounts of a fully ex-
tended product of 29 nucleotides in the absence of nevi-
rapine, although some cleavage of the PPT tract was ob-
served in the corresponding extension reactions. In the pres-
ence of the drug, there was enhanced PPT degradation be-
fore nucleotide incorporation and premature PPT removal
and this resulted in the inhibition of (+)-strand DNA syn-
thesis (Supplementary Figure S1B). These results are con-
sistent with an increased binding of the RNA/DNA com-
plex in an RNase H-competent mode that would facilitate
polymerase-independent cleavage of the PPT.
The combination of N348I and T369I affects the RNase H
cleavage window of the HIV-1 RT
We analyzed whether the reduced efficiency of PPT cleavage
shown by mutant RTs N348I and N348I/T369I could be
related to the positioning of the susceptible G↓A cleavage
site in the RNA template relative to the DNA polymerase
active site. For this purpose, we used RNA/DNA template-
primers with recessed DNA 3′ ends containing the PPT se-
quence with the G↓A cleavage site in the RNA located at a
distance of 16, 17 or 18 nucleotides from the 3′ end of the
DNA primer.
As shown in Figure 3A, the PPT29RNA in the 29/28mer
hybrid was efficiently cleaved at position –16 in reactions
carried out with the WT RT and the single mutants T369I,
T369V and T376S. Overall cleavage efficiencies of N348I
RT were similar to those determined for the WT enzyme
(Supplementary Table S4), although the N348I mutant pro-
duced a smaller amount of secondary products. A slight re-
duction in cleavage efficiency was observed with the double-
mutant N348I/T369I. In reactions carried out with this RT,
cleavage at position –16 occurred at a very slow rate, while
larger bands corresponding to cuts at positions 18 and 19
nucleotides away from the 3′ end of the primer were also
observed. Interestingly, when the cleavage window was one-
nucleotide longer, all tested RTs showed increased endonu-
cleolytic activity (Figure 3B and Supplementary Table S4).
However, cleavages at positions –17 and –18 were predom-
inant in reactions carried out with the N348I/T369I RT,
while all other RTs rendered a single product of 21 nu-
cleotides (corresponding to RNAs cleaved at position –17)
(Figure 3B). In assays carried out with the 29/30mer (i.e.
PPT29RNA/PPT30DNA), all RTs showed identical cleav-
age patterns (Figure 3C) with similar RNase H catalytic
rates, except for the single-mutant T369V that showed an
increased kobs in comparison with the other enzymes (Sup-
plementary Table S4). Taken together, the analyses with
template-primers of different lengths indicate that the com-
bination of N348I and T369I has an impact on the RNase
H cleavage window and reduces the RT’s ability to produce
shorter RNA products.
Data shown in Figure 3 were consistent with the re-
sults of RNase H cleavage assays carried out under
single-turnover conditions (Supplementary Figure S2).
RNA oligonucleotides of 21 bases resulting from cleav-
age of the G↓A bond at position –16 of template-primer
PPT29RNA/PPT28DNA represented 42.8% of all prod-
ucts in reactions catalyzed by the WT RT. However, the
efficiency of this cleavage was almost negligible in reac-
tions carried out with mutants N348I and N348I/T369I.
On the other hand, all RTs showed the same specificity
with the 29/30mer and rendered the 21-nucleotide prod-
uct with yields above 90%. Interestingly, cleavage pat-
terns obtained with the N348I RT and template-primer
PPT29RNA/PPT29DNA revealed its higher tendency to
produce shorter oligonucleotides in comparison with the
double mutant. Thus, the 21-base oligonucleotide repre-
sented 25.4% of all cleavage products, while this value
was reduced to 13.9% in reactions catalyzed by the
N348I/T369I RT.
Additional experiments also showed that the differences
between WT, N348I and N348I/T369I RTs were reduced
when the assays were carried out in the presence of nevi-
rapine or efavirenz (Supplementary Figure S3). Short cleav-
age products representing cuts at positions –17, –16 or even
–15 were obtained with all three enzymes in the presence
of NNRTIs. Although the double mutant showed a slower
cleavage rate in comparison with the WT enzyme, these dif-
ferences were only detectable for the shorter cleavage prod-
ucts (i.e. those resulting from cuts at position –15).
RNA templates containing the PPT sequence are resilient
to cleavage. In order to test whether the observed differences
in cleavage specificity between the mutant N348I/T369I
and the other studied RTs could be attributed to the spe-
cific PPT sequence, we compared the RNase H cleavage
patterns of WT and mutant RTs N348I and N348I/T369I
using two heteropolymeric RNA/DNA template-primers.
First, with the 31/21mer (31Trna/21P) we found that in
the absence of the drug, the major cleavage site for the WT
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Figure 3. Effect of HIV-1 RT connection subdomain mutations on the RNase H cleavage window. Time courses of the RNase H cleavage reaction were
obtained under multiple-turnover conditions with template-primers that mimic (−) strand DNA synthesis intermediates with PPT-containing templates:
(A) PPT29RNA/PPT28DNA, (B) PPT29RNA/PPT29DNA and (C) PPT29RNA/PPT30DNA. Reactions were carried out in the presence of RT and
template-primers at concentrations of 50 and 25 nM, respectively. Aliquots were removed at 20 s, 40 s and 1, 2, 3 and 4 min. Template-primer nucleotide
sequences and relevant cleavage sites are shown below the corresponding gels. Time courses of RNase H reactions obtained for each enzyme are shown on
the right. Represented values were determined from three independent experiments [means ± standard deviations (error bars)]. The calculated kobs values
are given in Supplementary Table S4.
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RT is at position –16 (Supplementary Figure S4). As de-
scribed above for the PPT29RNA/PPT28DNA complex,
the N348I RT shows reduced cleavage efficiency at this po-
sition, while the activity of the double mutant is consider-
ably reduced. However, when nevirapine is included in the
reaction, the three RTs were efficient in generating a 26-nt
RNA (i.e. resulting from cleavage at position –16), as well
as one-nucleotide shorter products. However, shorter prod-
ucts resulting from cleavage at position –13 appeared only in
reactions catalyzed by the WT enzyme. On the other hand,
experiments carried out with the D30RNA/25PGA hybrid
revealed that primary cleavage of D30RNA by WT RT oc-
curs at position –18, while secondary cuts are observed at
positions –16, –15 and –14 (Supplementary Figure S4). In-
terestingly, in the absence of drugs, differences in the cleav-
age rates at position –18 between the three tested RTs were
very small. However, secondary cleavages at positions –15
and –14 were almost negligible in reactions carried out with
the double mutant in the presence of nevirapine. These re-
sults are consistent with an impaired ability to cleave shorter
RNAs by the double-mutant N348I/T369I RT.
PPT stability and initiation of (+)-strand DNA synthesis in
the presence of NNRTIs
Nucleotide incorporation at the 3′ end of the PPT can be in-
hibited in the presence of NNRTIs. In addition, the RNase
H activity of the RT can also affect the integrity of the PPT
(Supplementary Figure S1B). Experiments carried out with
the PPT17r/PPT29DNA template-primer showed that the
stability of the PPT might be different depending on the
NNRTI used in the assays. Thus, rilpivirine and efavirenz
are more potent than nevirapine and etravirine in stimu-
lating PPT degradation (Figure 4A). Cleavage of the PPT
in these assays can be detected only if the template-primer
binds in a polymerase-independent mode, although hybrids
were designed to favor a polymerase-dependent binding
mode. BothWT andN348I/T369I RTs showed similar PPT
cleavage patterns in the presence of NNRTIs. However, at
higher concentrations of nevirapine (i.e. 1––5 M), degra-
dation of the PPT by the WT enzyme was increased rela-
tively to the doublemutant. Since the efficiency of the exten-
sion of trimmedPPTs is very low, these results imply that the
initiation of (+)-strandDNA synthesismight be impaired in
the presence of NNRTIs.
In addition, significant inhibition of (+)-strand DNA
synthesis due to cleavage of the PPT primer in reactions
catalyzed by the WT RT was observed with rilpivirine and
efavirenz at concentrations that were 10 times lower than
those needed for nevirapine and etravirine (Figure 4B). Un-
like the WT RT, the combination of mutations N348I and
T369I facilitates the extension of the PPT primer to pro-
duce a full-length product of 29 nucleotides in the pres-
ence of nevirapine (Figure 4B). These compensatory ef-
fects were also observed with efavirenz and etravirine, al-
though the differences in the amount of extended product
obtained with WT and mutant RTs were reduced. On the
other hand, in the presence of rilpivirine, we observed a
significant inhibition of PPT extension with both WT and
N348I/T369I RTs. AlthoughWT RT increased PPT degra-
dation under these conditions, both RTs were very ineffi-
cient in extending the primer and rendered low amounts
of fully extended product. Interestingly, these inhibitory ef-
fects were not observedwith amutantRT that contained the
rilpivirine resistance-associated mutation E138K combined
with the two substitutions in the connection subdomain (i.e.
E138K/N348I/T369I) (Supplementary Figure S5). Taking
into account the effects on PPT degradation and primer
elongation, our results reveal that rilpivirine is the most effi-
cient and potent inhibitor of (+)-strand DNA synthesis ini-
tiation, among the NNRTIs analyzed in this study.
DISCUSSION
HIV-1 RT connection subdomain mutations are selected
during therapy with NNRTIs, particularly with nevirapine
(30,31). A recent search in the Stanford HIV Drug Resis-
tance Database (http://hivdb.stanford.edu/; accessed on 22
September 2014) showed that the prevalence of N348I and
T369I in untreated patients infected with HIV-1 group M
subtype B was lower than 0.1%, while in patients treated
with nevirapine, these figures went up to 11.1 and 1.5% for
N348I and T369I, respectively (P < 0.001 in both cases).
Significant increases of prevalence were also observed for
patients treated with efavirenz where N348I and T369I were
present in 8.7% and 2.2% of all isolates, respectively (P <
0.001). Similar analyses carried out with T369V and A376S
only reveal a significant increase of prevalence in the case
of T369V and nevirapine (8.8% in nevirapine-treated pa-
tients versus 3.0% in untreated individuals). The studied
amino acid substitutions had a relatively small impact on
NNRTI resistance (Table 1), but the combination of N348I
and T369I was previously described as conferring a serious
defect in viral replication capacity (28).
In agreement with previous reports, our results demon-
strate that RT functions can be modulated by RT con-
nection subdomain mutations despite the distant loca-
tion of Asn348 and Thr369, relative to the DNA poly-
merase and RNase H active sites, and the NNRTI binding
pocket. Several mechanisms have been proposed to explain
how RT connection subdomain mutations could influence
NNRTI resistance ((19,30,32,33); reviewed in (27)). Thus,
mutations that affect template-primer binding could indi-
rectly modulate NNRTI binding (e.g. A376S) (31). Reduced
RNase H activity mediated by N348I and other mutations
in its vicinity increases the stability of the RT/template-
primer/NNRTI complex and therefore allows more time
for dissociation of the NNRTI from the RT/template-
primer binary complex (26). The correct positioning of the
template-primer in the nucleic acid binding cleft may also
have an influence on the dynamics of NNRTI binding. This
is particularly important during the initiation of (+)-strand
DNA synthesis where the PPT is used as a primer for DNA
elongation and needs to be removed by the RNase H activ-
ity of the RT. The initiation of (+)-strand DNA synthesis
is characterized by slow polymerization where high dNTP
levels are needed for the incorporation of the first two nu-
cleotides, followed by rapid dissociation of the RT and fre-
quent kinetic pauses during primer extension (18,41).
Our data confirm that initiation of (+)-strand DNA syn-
thesis during reverse transcription is significantly affected
by N348I (19), but we also show that other individual mu-
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Figure 4. Effects of NNRTIs on PPT susceptibility to RNase H cleavage by WT and mutant N348I/T369I RTs. (A) Cleavage of the PPT primer in the
presence of nevirapine, etravirine, efavirenz and rilpivirine. Reactions were carried out in the presence of 25-nM template-primer (PPT29DNA/PPT17r) and
125-nMRT. The RT and the inhibitor were preincubated at room temperature during 5 min. In reactions carried out with WT RT aliquots were taken 20 s
after adding the template-primer, while in the case of the N348I/T369I RT time points were collected 60 s after adding the PPT29DNA/PPT17r complex.
Nevirapine (NVP) and etravirine (ETV) concentrations in the assays were 0, 0.08, 0.16, 0.31, 0.625, 1.25, 2.5 and 5 M. For efavirenz (EFV) and rilpivirine
(RPV) the concentrations used were 0, 0.04, 0.08, 0.16, 0.20, 0.31, 0.625, 1.25, 2.5 and 5M.Graphical representations of the results obtained withWT and
mutant N348I/T369I RTs are shown on the right. Represented values were determined from three independent experiments [means ± standard deviations
(error bars)]. P stands for uncleaved PPT oligonucleotide. (B) PPT primer extension assays carried out in the presence of NNRTIs. Reactions were carried
out in the presence of 25-nM RT, 25-nM template-primer (PPT29DNA/PPT17r) and all four dNTPs (each at 200-M concentration). Aliquots were
withdrawn at 0.5, 1, 2, 3, 4 and 5 min.
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tations in the RT connection subdomain such as T369I or
V or T376S do not seem to affect PPT removal. Never-
theless, we also found that T369I enhances the effects of
N348I RT by producing a further reduction of its RNase
H activity. The lower replication capacity of HIV-1 bearing
RT mutations N348I/T369I (28) could be attributed to the
reduced RNase H cleavage efficiency of the N348I/T369I
RT observed in our studies with PPT-containing template-
primers as well as conventional heteropolymeric hybrids.
Nevertheless, nevirapine and efavirenz are strong enhancers
of the PPT removal reaction (Figure 2A), while N348I and
in a larger extent N348I/T369I counteract these effects. The
results obtained with the WT RT and the single-mutant
N348I RT in the presence of nevirapine and efavirenz are
similar to those previously reported by Biondi et al. (19),
although in their assays the suppressive effect of N348I was
observed only with nevirapine. Differences between their re-
sults and ours could be attributed to the NNRTI concentra-
tion (a higher amount of efavirenz is needed to achievemax-
imum levels of PPT cleavage) or to amino acid sequence dif-
ferences found in the RTs used in those experiments. Our re-
sults also show that rilpivirine has a small stimulatory effect
on PPT removal during (+)-strand DNA synthesis in com-
parison with nevirapine and efavirenz, although this effect
cannot be suppressed by RT connection subdomain mu-
tations. In addition, recent studies have shown that N348I
produces a moderate increase (around 2-fold) in the levels
of rilpivirine resistance conferred by E138K, although the
reduced DNA polymerase and RNase H activities of the
N348I mutant restrict the emergence of the rilpivirine resis-
tance mutation due to the diminished replication capacity
of the virus (42).
The effects of nevirapine on PPT removal have been ex-
plained by its capacity to favor the interaction between the
RT and the template-primer in a polymerase-independent
binding mode (16). In their report, these authors also
mention that similar effects were observed with efavirenz,
although evidence of this behavior was not presented.
By using a blunt-ended RNA/DNA template-primer with
a recessed RNA 3′ end, we show that rilpivirine and
efavirenz have a stronger tendency to adopt a polymerase-
independent binding mode in comparison with nevirapine
and etravirine, and this could facilitate the premature degra-
dation of the PPT (Figure 4). However, the differences be-
tween WT and N348I/T369I RT were more pronounced
with nevirapine. The stability of the PPT primer at high con-
centrations of nevirapine was lower in the presence of WT
RT than in the presence of the double mutant. Another im-
portant conclusion of these experiments is that rilpivirine
seems to be effective in promoting the degradation of the
PPT and inhibiting its extension in the presence of dNTPs,
being almost equally effective against the WT enzyme and
the doublemutantN348I/T369I. An intriguing observation
relates to differences observed between the two closely re-
lated diarylpyrimidines. Unlike rilpivirine, etravirine has a
minor effect on trimming the PPT primer. Both inhibitors
are chemically similar, although they adopt a slightly differ-
ent conformation in the NNRTI binding site (43–45) where
the cyanovinyl moiety of rilpivirine makes extensive con-
tacts with Phe227 and Trp229. These interactions, absent in
the etravirine complex, affect the positioning of the primer
at the DNA polymerase active site and could facilitate nu-
cleic acid binding in a polymerase-independent orientation.
Our studies with RNA/DNA complexes of different
lengths show for the first time that N348I influences the
RNase H cleavage window and that this effect is enhanced
by the presence of T369I. WT and N348I/T369I RTs had
similar efficiencies and cleavage patterns when RNA prod-
ucts of 21 nucleotides were generated (i.e. resulting from
cleavage at position –18). However, when the PPT sequence
resistant to hydrolysis was made one or two nucleotides
shorter, the differences in cleavage patterns between WT
and N348I/T369I RTs became evident. In addition, exper-
iments carried out with the 29/28mer hybrid showed that
the double mutant had significantly reduced efficiency in
the generation of shorter RNAs, in comparison with the
WT RT or the single mutants T369I, T369V and T376S.
The different cleavage windows finally result in the con-
servation of the PPT primer in the presence of nevirap-
ine, etravirine and efavirenz, and a higher efficiency of (+)-
strand DNA synthesis in reactions catalyzed by the double-
mutant N348I/T369I.
A structural interpretation of these differences is difficult
since both mutations map away from the DNA polymerase
and RNase H active sites. However, Asn348 and Thr369 are
surrounded by hydrophobic and aromatic residues in the
HIV-1 RT structure and mutations to Ile in both cases
could enhance hydrophobicity and make stronger interac-
tions in p66 and p51. An enhanced rigidity of the mutant
RT would be consistent with its reduced ability to cleave
shorter RNAs. In agreement with this proposal, it has been
suggested that a hydrogen bond between Tyr427 and Asn348
could be important in stabilizing the C-terminal region of
p51, and this could have an impact on substrate positioning
(46). The impact on drug resistance caused by mutations
in the connection subdomain has been attributed to con-
formational changes that influence the orientation and po-
sitioning of the template-primer (22). Moreover, the likely
increased rigidity caused by mutations such as N348I im-
poses constraints in the structure of the NNRTI binding
pocket. As a result, subtle but significant changes in the
DNA polymerase and RNase H active sites may occur, and
allosteric effects could be responsible for the differences ob-
served between mutant RTs in their susceptibility to NNR-
TIs (22,47,48).
Neither Asn348 nor Thr369 interact directly with the
RNA/DNA hybrid (22,47,48), although Thr369 locates at
-helix K in p66 and through interactions with -helix L in
p51 (residues 394–404) could have an influence on the con-
formation of the DNA strand (22). The -helix L of p51
is part of the so-called ‘RNase H primer grip’ (47). Muta-
tions affecting residues of the RNase H primer grip often
reduce polymerization-independent cleavage of the RNA
template (49). A recent report has shown that the A400T
mutation reduces RNase H activity while producing a small
increase in resistance to nevirapine and efavirenz (50). Addi-
tional hydrogen bonding between the side chains of Thr400
and Glu396 has been proposed by those authors to explain
changes in the conformation of the RNase H primer grip
that could account for the altered RNase H activity of mu-
tants affecting Ala400. Unlike mutations analyzed in our
study whose prevalence in untreated patients is lower than
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7.5%, A400T is a common polymorphism in HIV-1 group
M isolates with a prevalence of nearly 56% in untreated
patients. Modeling studies have shown little differences be-
tween ternary complexes containing the WT or the double-
mutant N348I/T369I RT, associated with a DNA/DNA
template-primer and nevirapine (51). However, it is clear
from our studies that when associated with RNA/DNA
complexes, the combination of mutations N348I and T369I
has amajor impact in theRNaseH activity of theRT. These
results are also in agreement with the notion that a num-
ber of distal connection subdomainmutations contribute to
drug resistance by altering the dynamic properties of the RT
and contact networks involving amino acid residues in the
viral enzyme, identified by using molecular dynamics (51).
In summary, our studies show that in general all NNRTIs
favor the premature removal of the PPT at the initiation of
(+)-strand DNA synthesis. However, rilpivirine appears to
bemost effective at inhibiting PPT elongation, as well as de-
creasing its availability due to RNase H-mediated cleavage.
Although N348I and more efficiently N348I/T369I could
revert some of the effects of NNRTIs on PPT removal, their
efficiency with rilpivirine is almost negligible. The decreased
RNase H activity conferred by both mutations is appar-
ently caused by a loss in the ability of the HIV-1 RT to ren-
der shorter RNA products, suggesting that those mutations
could affect the rigidity of a hypothetical hinge located at
the connection subdomain of the RT and linking the two
functional domains of the enzyme. Our study provides in-
sight on how connection subdomain mutations could af-
fect the dynamics of coupling between HIV-1 RT activities,
a mechanism that is relevant to understand antiretroviral
drug resistance, and in amore general perspective the effects
of distant mutations on the catalytic activity of multifunc-
tional enzymes.
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